trending Market Intelligence /marketintelligence/en/news-insights/trending/pwihu44wdfcezjfaiespsw2 content esgSubNav
In This List

Daiichi Sankyo files regulatory application for hypertension drug in Japan

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Daiichi Sankyo files regulatory application for hypertension drug in Japan

Daiichi Sankyo Co. Ltd. submitted a new drug application for esaxerenone to the Japanese Pharmaceutical and Medical Devices Agency.

The Tokyo-based drugmaker said it expects the drug to provide a new option to treat hypertension. The application is based on phase 3 trial data for the drug, which was evaluated in patients with essential hypertension.

An estimated 43 million people over 30 years old in Japan have hypertension, according to the Japan National Health and Nutrition Survey 2012. Essential hypertension accounts for 90% of hypertensive patients.

Separately, San Francisco-based Exelixis Inc., which helped develop esaxerenone, said the regulatory application triggered a $20 million milestone payment from Daiichi Sankyo.